(Q45897479)

17 December 2017

title

Cost-effectiveness of heart failure therapies (English)

1 reference

17 December 2017

cost-effectiveness analysis

main subject

1 reference

1 reference

1

Luis E Rohde

1 reference

17 December 2017

author name string

Eduardo G Bertoldi

series ordinal

2

1 reference

17 December 2017

Livia Goldraich

series ordinal

3

1 reference

17 December 2017

Carísi A Polanczyk

series ordinal

4

1 reference

17 December 2017

language of work or name

English

0 references

publication date

23 April 2013

1 reference

17 December 2017

Nature Reviews Cardiology

published in

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

338-354

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/nrcardio.2013.60

exact match

0 references

cites work

The epidemiology and pathophysiology of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Heart failure and the aging population: an increasing burden in the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Epidemiology and risk profile of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Chronic non-communicable diseases in Brazil: burden and current challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

What are the costs of heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Heart failure: incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Medical economics and the assessment of value in cardiovascular medicine: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of oral antiplatelet agents--current and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

What do international pharmacoeconomic guidelines say about economic data transferability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost and cost-effectiveness studies in heart failure research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Pharmacoeconomics: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Long-term cost-effectiveness of disease management in systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of captopril therapy after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of spironolactone in patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Eplerenone is not superior to older and less expensive aldosterone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of implantable cardioverter-defibrillators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The effect of cardiac resynchronization on morbidity and mortality in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cardiac-resynchronization therapy for the prevention of heart-failure events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cardiac-resynchronization therapy for mild-to-moderate heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Heart transplant and left ventricular assist device costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of pediatric heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Heart Transplantation Report--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Long-term use of a left ventricular assist device for end-stage heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Use of a continuous-flow device in patients awaiting heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Advanced heart failure treated with continuous-flow left ventricular assist device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost utility evaluation of extracorporeal membrane oxygenation as a bridge to transplant for children with end-stage heart failure due to dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of carvedilol for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Heart failure disease management programs: A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Hospital cost effect of a heart failure disease management program: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Methodological issues in cost-effectiveness studies: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Searching for cost effectiveness thresholds in the NHS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Long term health care consumption and cost expenditure in systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Assessment of the clinical outcomes and cost-effectiveness of the management of systolic heart failure in Chinese patients using a home-based intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of supervised exercise therapy in heart failure patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Cost-effectiveness analysis of transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.60

[Cost of heart failure in the Unified Health System]

31 March 2020

1 reference

12 December 2020

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

1 reference

12 December 2020

Cost-effectiveness of telephonic disease management in heart failure

1 reference

12 December 2020

Economic assessment of cardiac resynchronization therapy.

1 reference

12 December 2020

Cost-effectiveness analysis of bisoprolol treatment for heart failure

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2013.60

1 reference

17 December 2017

Dimensions Publication ID

1038803707

0 references

1 reference

17 December 2017